Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-23T15:37:16.626Z Has data issue: false hasContentIssue false
  • English
  • Français

Are we done with trazodone? The potential for damage by m-CPP – a metabolite of trazodone

Published online by Cambridge University Press:  24 June 2014

Richard E Kast
Richard E Kast*
Affiliation:
Department of Psychiatry, University of Vermont, Burlington 05401 Vermont
*
Dr Richard E. Kast, Department of Psychiatry, University of Vermont, 2 Church Street, Burlington VT 05401. Tel: +802-863-2462 E-mail: rekast@email.com
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Comment & Critique
Information
Acta Neuropsychiatrica , Volume 19 , Issue 3 , June 2007 , pp. 220 - 221
Copyright
Copyright © 2007 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Rotzinger, S, Fang, J, Baker, GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998;26:572–575.Google ScholarPubMed
Maes, M, Westenberg, H, Vandoolaeghe, Eet al. Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. J Clin Psychopharmacol 1997;17:358–364.CrossRefGoogle ScholarPubMed
Feuchtl, A, Bagli, M, Stephan, Ret al. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. Pharmacopsychiatry 2004;37:180–188.CrossRefGoogle ScholarPubMed
Porter, RH, Benwell, KR, Lamb, Het al. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol 1999;128:13–20.CrossRefGoogle ScholarPubMed
Sabbe, B, Hulstijn, W, Maes, M, Pier, M, Scharpe, S, Zitman, F. Psychomotor slowing, neuroendocrine responses, and behavioral changes after oral administration of meta-chlorophenylpiperazine in normal volunteers. Psychiatry Res 2001;105:151–163.CrossRefGoogle ScholarPubMed
Ghaziuddin, N, Welch, K, Greden, J.Central serotonergic effects of m-chlorophenylpiperazine (mCPP) among normal control adolescents. Neuropsychopharmacology 2003;28:133–139.CrossRefGoogle ScholarPubMed
Silverstone, PH, Rue, JE, Franklin, Met al. The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers. Int Clin Psychopharmacol 1994;9:173–178.CrossRefGoogle ScholarPubMed
Walker, EA, Kohut, SJ, Hass, RW, Brown, EK Jr, Prabandham, A, Lefever, T. Selective and nonselective serotonin antagonists block the aversive stimulus properties of MK212 and m-chlorophenylpiperazine (mCPP) in mice. Neuropharmacology 2005;49:1210–1219.CrossRefGoogle ScholarPubMed
Frampton, AE, Andrews, JC, Parfitt, A, Jagroop, IA, Mikhailidis, DP, Henry, JA. Does meta-chlorophenylpiperazine (mCPP) activate human platelets? Platelets 2006;17:30–36.CrossRefGoogle ScholarPubMed
Kubera, M, Maes, M, Kenis, G, Kim, YK, Lason, W. Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res 2005;134:251–258.CrossRefGoogle ScholarPubMed
Leone, M, Attanasio, A, Croci, Det al. The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: a controlled study. Neurology 2000;55:136–139.CrossRefGoogle ScholarPubMed
Johnson, KW, Nelson, DL, Dieckman, DKet al. Neurogenic dural protein extravasation induced by meta-chlorophenylpiperazine (mCPP) involves nitric oxide and 5-HT2B receptor activation. Cephalalgia 2003;23:117–123.CrossRefGoogle ScholarPubMed
Nebigil, CG, Maroteaux, L. Functional consequence of serotonin/5-HT2B receptor signaling in heart: role of mitochondria in transition between hypertrophy and heart failure? Circulation 2003;108:902–908.CrossRefGoogle ScholarPubMed
Jaffre, F, Callebert, J, Sarre, Aet al. Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts. Circulation 2004;110:969–974.CrossRefGoogle ScholarPubMed
Nilsson, T, Longmore, J, Shaw, Det al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 1999;372:49–56.CrossRefGoogle ScholarPubMed
Lamping, KG. Response of native and stimulated collateral vessels to serotonin. Am J Physiol 1997;272:H2409–H2415.Google ScholarPubMed